The Review of Austrian Economics

, Volume 30, Issue 2, pp 215–233 | Cite as

Don’t eat the brown acid: Induced ‘malnovation’ in drug markets

  • Audrey RedfordEmail author


Title II, the Controlled Substances Act (CSA), of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (CDAPCA) created the present system of drug scheduling and regulation. This paper illustrates how the CSA created the incentives for induced ‘malnovation’ (innovation intended to circumvent legislation, and thus foil policymakers’ intended ends) into drug markets, namely “designer drugs.” As a result of this induced malnovation, drug markets have not only increased in the variance of products available that are often sold under similar street names, but there is also a tendency towards creating more dangerous drugs in an attempt to stay outside of the regulation.


Induced malnovation Comprehensive Drug Abuse Prevention and Control Act of 1970 Controlled Substances Act Designer drugs 

JEL Codes

K42 L51 O31 


  1. A potent ‘designer’ drug. (1991). The New York Times, February 3. Accessed at Accessed on November 15, 2014.
  2. Anti-Drug Abuse Act. (1986). Pub. L. No. 99-570. 100 Stat. 3207, 1-192.Google Scholar
  3. Alchian, A., & Allen, W. R. (1964). University economics. Belmont: Wadsworth.Google Scholar
  4. Becker, G. S., Murphy, K. M., & Grossman, M. (2006). The market for illegal goods: the case of drugs. Journal of Political Economy, 114(1), 38–60.CrossRefGoogle Scholar
  5. Bennett, D. (2005). Dr. ecstasy. The New York Times Magazine, January 30. Accessed at Accessed on July 18, 2015.
  6. Bever, F. (2015). Illicit version of painkiller fentanyl makes heroin deadlier. NPR Shots: Health News from NPR, August 27. Accessed at Accessed on March 2, 2016.
  7. Bush, D. M., & Woodwell, D. A. (2014). Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ Report, October 16. Accessed at Accessed on July 18, 2015.
  8. Capriola, M. (2013). Synthetic cathinone abuse. Clinical Pharmacology: Advances and Applications, 5, 109–115.Google Scholar
  9. Comprehensive drug abuse prevention & control act. (1970). Pub. L. No. 91–513, 84 Stat. 1236–1295.Google Scholar
  10. Controlled substances act. (1970). Pub. L. No. 91-513, 84 Stat. 1242–1284.Google Scholar
  11. Controlled substances analogue enforcement act. (1986). Pub. L. No. 99-570, 100 Stat. 3207, 13–14.Google Scholar
  12. Crider, R. (1986). Phencyclidine: Changing abuse patterns. In D. H. Clouet (Ed.), Phencyclidine: An update, NIDA research monograph 64 (pp. 163–173). Rockville: National Institute on Drug Abuse.Google Scholar
  13. Dangerous drug diversion control act. (1984). Pub. L. No. 98-473, 98 Stat. 2070–2077.Google Scholar
  14. Drug Enforcement Administration. (2013). National drug threat assessment summary 2013. U.S. Department of Justice, November. Accessed at Accessed on July 25, 2015.
  15. Drug Enforcement Administration. (2014). Schedules of controlled substances: temporary placement of 10 synthetic cathinones into schedule I. 21 CFR Part 1308, Docket No. DEA-386. Drug Enforcement Administration, Department of Justice, March 7. Accessed at Accessed on July 20, 2015.
  16. Drug Enforcement Administration, Office of Division Control. (2015). List of controlled substances, July 2015. Accessed at Accessed on July 23, 2015.
  17. Garey, R. E. (1979). PCP (phencyclidine): an update. Journal of Psychedelic Drugs, 11(4), 265–275.CrossRefGoogle Scholar
  18. Garey, R. E., Weisberg, L. A., & Heath, R. G. (1977). Phencyclidine: an overview. Journal of Psychedelic Drugs, 9(4), 280–285.CrossRefGoogle Scholar
  19. Griffin, O. H. (2012). Is the government keeping the peace or acting like our parents? Rationales for the legal prohibitions of GHB & MDMA. Journal of Drug Issues, 42(3), 247–262.CrossRefGoogle Scholar
  20. Griffin, D., Black, N., & DiCarlo, P. (2013). 9 things everyone should know about the drug Molly. CNN Health, Erin Burnett OutFront, November 23. Accessed at Accessed on November 14, 2014.
  21. Henderson, G. L. (1988). Designer drugs: past history and future prospects. Journal of Forensic Sciences, 33(2), 569–575.CrossRefGoogle Scholar
  22. Jauregui, A. (2014). Fentanyl-laced heroin linked to dozens of deaths in northeast. Huffington Post, Crime, February 3. Accessed at Accessed on November 15, 2014.
  23. Kedmey, D. (2014). DEA launches nationwide raid on synthetic drug dealers. TIME, May 7. Accessed at Accessed on March 2, 2016.
  24. Khazan, O. (2013). Synthetic drugs are multiplying too fast for regulators to outlaw them. The Atlantic, June 27. Accessed at Accessed on March 2, 2016.
  25. King, L. A., & Kicman, A. T. (2011). A brief history of ‘new psychoactive substances’. Drug Testing and Analysis, 3, 401–403.CrossRefGoogle Scholar
  26. Kirzner, I. M. (1985). The perils of regulation: A market-process approach. Discovery and the capitalist process. Chicago: University of Chicago Press.Google Scholar
  27. Kreit, A. (2013). Controlled substances, uncontrolled law. Albany Government Law Review, 331(6), 331–357.Google Scholar
  28. Kutner, M. (2015). College kids are unknowingly rolling on bath salts. Newsweek, March 25. Accessed at Accessed on March 2, 2016.
  29. LaBarbera, M., & Wolfe, T. (1983). Characteristics, attitudes and implications of fentanyl use based on reports from self-identified fentanyl users. Journal of Psychoactive Drugs, 15(4), 293–301.CrossRefGoogle Scholar
  30. McGlothilin, W. H. (1973). Amphetamines, barbiturates and hallucinogens: An analysis of use, distribution and control. Washington, DC: Department of Justice, Bureau of Narcotics and Dangerous Drugs.Google Scholar
  31. Miron, J. A. (2001). Violence, guns, and drugs: a cross‐country analysis. Journal of Law and Economics, 44(2), 615–633.CrossRefGoogle Scholar
  32. Palermo, D. (1986). “Chemist, alleged colleague arrested in N. Hollywood: 2 accused of operating synthetic heroin lab. Los Angeles Times, April 11. Accessed at Accessed on July 15, 2015.
  33. Sager, B. (1985). Designer drugs. Department of Justice. National Archives Identifier: 37931. Local Identifier: 170.91. The National Archives Catalog. Accessed at*:designer%20drugs*. Accessed on July 14, 2015.
  34. Shulgin, A. T. (1975). Drugs of abuse in the future. Clinical Toxicology, 8(4), 405–456.CrossRefGoogle Scholar
  35. Shulgin, A. T., & Shulgin, A. (1991). PiKHAL: A chemical love story. Berkeley: Transform Press.Google Scholar
  36. Svrluga, S. (2014). Fatal heroin and fentanyl overdoses rise in Maryland. The Washington Post, November 7. Accessed at Accessed on November 15, 2014.
  37. Thornton, M. (1991). The economics of prohibition. Salt Lake City: University of Utah Press.Google Scholar
  38. United Nations. (1961). Single convention on narcotic drugs. New York: United Nations.Google Scholar
  39. United States v. Forbes et al. (1992). 806F. Supp. 232. District of Colorado.Google Scholar
  40. Untied States v. Washam. (2002). 312 F. 3d 926. United States Court of Appeals, Eighth Circuit.Google Scholar
  41. Weber, B. (2014). Alexander Shulgin, psychedelia researcher, dies at 88. The New York Times, June 7. Accessed at Accessed on November 20, 2014.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Agricultural & Applied EconomicsTexas Tech UniversityLubbockUSA

Personalised recommendations